Clinical trials: 15-20% weight loss Real world average: ~12% for full-year users Early stoppers (common): only 3.6% weight loss Side effects: 50% experience nausea, 33% experience diarrhea Ask: What percentage of your patients achieve and maintain their weight loss goals? 5
Brintha Vasagar, MD, MPH, a family medicine doctor in Wisconsin, recommends that people who are trying self-injection for the first time speak with their healthcare team for tips on where and how to inject the medication
10.1038/nchembio.2239 Nat Chem Biol
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed to treat type 2 diabetes and obesity
Other studies suggest that it could be used for conditions like dementia and heart disease
It is different from ordinary pharmacy benefit coverage because it may involve its own eligibility rules, documentation requirements, and prior authorization process